TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties. It has been shown to reverse cognitive deficits in an Alzheimer's disease (AD) mouse model, thus serving as a valuable tool for Alzheimer’s disease research [1].

TrkB-IN-1, administered to 5XFAD mice via oral gavage at doses of 7.25 mg/kg, 21.8 mg/kg, and 43.6 mg/kg over three months, dose-dependently activated the TrkB signaling cascade in the hippocampus, with corresponding increases in the ratios of p-TrkB/TrkB, p-Akt/Akt, and p-ERK/ERK [1]. Additionally, a five-day treatment with TrkB-IN-1 at the same doses attenuated Aβ deposition and ameliorated memory deficits in the 5XFAD mice [1]. Pharmacokinetic parameters for TrkB-IN-1, at an oral gavage dose of 36 mg/kg, revealed an oral bioavailability of 10.5%, a Cmax of 129 ng/mL, a Tmax of 0.5 h, and a T1/2 of 3.66 h [1].